thiamazole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1745 60-56-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methimazole
  • methylimidazolethiol
  • thyrozol
  • thymidazole
  • thymidazol
  • thycapzol
  • thiamazole
  • tapazole
  • methymazol
A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.
  • Molecular weight: 114.17
  • Formula: C4H6N2S
  • CLOGP: -0.34
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 15.27
  • ALOGS: -1
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 8.76 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.86 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.70 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 200 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
June 21, 1950 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Agranulocytosis 402.51 14.05 149 9454 24985 63454434
Thyrotoxic crisis 295.04 14.05 58 9545 818 63478601
Hyperthyroidism 231.10 14.05 86 9517 14587 63464832
Antithyroid arthritis syndrome 74.61 14.05 10 9593 4 63479415
Hypothyroidism 69.47 14.05 55 9548 42577 63436842
Choanal atresia 59.65 14.05 9 9594 20 63479399
Exophthalmos 43.80 14.05 14 9589 1502 63477917
Neutropenia 40.81 14.05 85 9518 174920 63304499
Blood thyroid stimulating hormone decreased 38.08 14.05 17 9586 4573 63474846
Drug-induced liver injury 34.14 14.05 36 9567 40186 63439233
Jaundice cholestatic 33.31 14.05 18 9585 7306 63472113
Anti-neutrophil cytoplasmic antibody positive vasculitis 31.51 14.05 13 9590 2886 63476533
Goitre 30.93 14.05 16 9587 5945 63473474
Dysmorphism 30.87 14.05 12 9591 2284 63477135
Thyroxine free increased 29.02 14.05 9 9594 875 63478544
Cardiac arrest 27.72 14.05 50 9553 92495 63386924
Cardiac failure 26.49 14.05 48 9555 89094 63390325
Mucocutaneous candidiasis 25.90 14.05 4 9599 11 63479408
Pulmonary alveolar haemorrhage 25.58 14.05 13 9590 4655 63474764
Aplasia cutis congenita 25.52 14.05 5 9598 69 63479350
Polyarthritis 25.43 14.05 17 9586 10129 63469290
Arthropathy 25.16 14.05 3 9600 234789 63244630
Drug intolerance 24.65 14.05 8 9595 308653 63170766
Functional residual capacity increased 24.17 14.05 5 9598 92 63479327
Insulin autoimmune syndrome 23.37 14.05 5 9598 109 63479310
Oropharyngeal pain 23.30 14.05 47 9556 94440 63384979
Toxic nodular goitre 23.27 14.05 4 9599 25 63479394
Respiratory syncytial virus infection 23.18 14.05 14 9589 7004 63472415
Endocrine ophthalmopathy 22.74 14.05 7 9596 664 63478755
Drug interaction 22.53 14.05 81 9522 229050 63250369
Stevens-Johnson syndrome 22.36 14.05 23 9580 24927 63454492
Thyroid disorder 21.39 14.05 18 9585 15144 63464275
Eosinophilic pleural effusion 20.86 14.05 4 9599 49 63479370
Contraindicated product administered 20.53 14.05 4 9599 217644 63261775
Acquired epidermolysis bullosa 20.36 14.05 4 9599 56 63479363
Hypoglycaemia 19.99 14.05 34 9569 60031 63419388
Atrial fibrillation 19.78 14.05 50 9553 116586 63362833
Systemic lupus erythematosus 19.37 14.05 4 9599 208914 63270505
Sopor 19.09 14.05 20 9583 22144 63457275
Thyroid haemorrhage 19.07 14.05 4 9599 79 63479340
Thyroidectomy 19.04 14.05 7 9596 1143 63478276
Hypersensitivity vasculitis 18.40 14.05 10 9593 4102 63475317
Hepatitis cholestatic 18.39 14.05 12 9591 6866 63472553
Febrile neutropenia 18.27 14.05 49 9554 118400 63361019
Exposure during pregnancy 17.92 14.05 58 9545 155489 63323930
Rheumatoid arthritis 17.89 14.05 8 9595 253811 63225608
Symptom masked 17.85 14.05 6 9597 753 63478666
Electrocardiogram QT prolonged 17.61 14.05 32 9571 59498 63419921
Toxic goitre 17.56 14.05 3 9600 18 63479401
Multiple organ dysfunction syndrome 17.42 14.05 31 9572 56721 63422698
Therapeutic product effect decreased 17.30 14.05 4 9599 193183 63286236
Clinodactyly 17.19 14.05 4 9599 129 63479290
Thyroxine free abnormal 17.03 14.05 3 9600 22 63479397
Neuroglycopenia 16.26 14.05 5 9598 473 63478946
Spigelian hernia 15.78 14.05 3 9600 35 63479384
Microscopic polyangiitis 15.75 14.05 4 9599 187 63479232
Metabolic function test abnormal 15.53 14.05 4 9599 198 63479221
Autoimmune neutropenia 15.45 14.05 4 9599 202 63479217
Kidney transplant rejection 15.36 14.05 9 9594 4262 63475157
Acute generalised exanthematous pustulosis 15.30 14.05 13 9590 11086 63468333
Epiphysiolysis 15.14 14.05 3 9600 44 63479375
Tri-iodothyronine free increased 15.08 14.05 4 9599 222 63479197
Disorganised speech 14.87 14.05 6 9597 1259 63478160
Systemic candida 14.82 14.05 8 9595 3237 63476182
Product administered to patient of inappropriate age 14.77 14.05 8 9595 3260 63476159
Anaemia 14.70 14.05 85 9518 293345 63186074
Synovitis 14.64 14.05 5 9598 186913 63292506
Joint swelling 14.43 14.05 17 9586 327649 63151770
Renal infarct 14.09 14.05 6 9597 1441 63477978

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthyroidism 182.86 18.47 63 4264 10503 34942101
Thyrotoxic periodic paralysis 126.86 18.47 21 4306 128 34952476
Agranulocytosis 86.31 18.47 47 4280 23774 34928830
Thyrotoxic crisis 75.94 18.47 16 4311 399 34952205
Hypothyroidism 61.50 18.47 36 4291 20866 34931738
Polymerase chain reaction 43.55 18.47 8 4319 95 34952509
Kounis syndrome 43.44 18.47 15 4312 2503 34950101
Product administered to patient of inappropriate age 35.95 18.47 14 4313 3277 34949327
Albumin urine present 33.06 18.47 8 4319 376 34952228
Exomphalos 32.01 18.47 7 4320 209 34952395
Urine leukocyte esterase positive 31.44 18.47 8 4319 463 34952141
Haemoglobinuria 29.32 18.47 8 4319 607 34951997
Cholestatic liver injury 29.20 18.47 11 4316 2353 34950251
Goitre 28.96 18.47 10 4317 1668 34950936
Pericarditis fungal 28.23 18.47 6 4321 156 34952448
Mouth swelling 27.98 18.47 10 4317 1846 34950758
Urinary bladder rupture 25.33 18.47 5 4322 89 34952515
Urine ketone body present 24.40 18.47 8 4319 1140 34951464
Autoimmune thyroiditis 24.22 18.47 8 4319 1166 34951438
Glycosuria 23.81 18.47 8 4319 1229 34951375
Respiratory tract haemorrhage 23.60 18.47 8 4319 1262 34951342
Axial spondyloarthritis 23.60 18.47 6 4321 346 34952258
Drug-induced liver injury 23.47 18.47 23 4304 28809 34923795
Loss of proprioception 22.84 18.47 6 4321 394 34952210
Blood cyanide increased 22.06 18.47 4 4323 44 34952560
Tracheo-oesophageal fistula 21.83 18.47 6 4321 468 34952136
Coagulation time shortened 20.90 18.47 5 4322 224 34952380
Pulseless electrical activity 20.09 18.47 12 4315 7199 34945405
Cardiogenic shock 19.40 18.47 20 4307 26598 34926006
Blood sodium decreased 19.21 18.47 16 4311 16235 34936369
Thyroid operation 18.79 18.47 3 4324 14 34952590

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Agranulocytosis 432.45 13.20 187 12430 44843 79686928
Thyrotoxic crisis 339.36 13.20 70 12547 1214 79730557
Hyperthyroidism 318.40 13.20 123 12494 22086 79709685
Thyrotoxic periodic paralysis 120.05 13.20 21 12596 140 79731631
Hypothyroidism 109.86 13.20 80 12537 52312 79679459
Antithyroid arthritis syndrome 74.16 13.20 10 12607 4 79731767
Exophthalmos 49.38 13.20 16 12601 1714 79730057
Drug-induced liver injury 46.82 13.20 55 12562 66062 79665709
Goitre 46.60 13.20 21 12596 5518 79726253
Anti-neutrophil cytoplasmic antibody positive vasculitis 44.13 13.20 18 12599 3711 79728060
Polymerase chain reaction 39.67 13.20 8 12609 123 79731648
Product administered to patient of inappropriate age 37.25 13.20 18 12599 5535 79726236
Cardiac failure 36.94 13.20 78 12539 154764 79577007
Jaundice cholestatic 32.56 13.20 21 12596 11263 79720508
Kounis syndrome 32.15 13.20 15 12602 4267 79727504
Cardiac arrest 31.42 13.20 78 12539 172018 79559753
Endocrine ophthalmopathy 30.34 13.20 9 12608 719 79731052
Toxic goitre 29.18 13.20 5 12612 29 79731742
Pulseless electrical activity 28.25 13.20 21 12596 14139 79717632
Blood thyroid stimulating hormone decreased 28.04 13.20 15 12602 5701 79726070
Neutropenia 26.76 13.20 103 12514 287607 79444164
Albumin urine present 26.46 13.20 8 12609 683 79731088
Hepatitis cholestatic 26.43 13.20 20 12597 13832 79717939
Polyarthritis 26.39 13.20 19 12598 12183 79719588
Pericarditis fungal 25.87 13.20 6 12611 182 79731589
Thyroxine free increased 25.69 13.20 9 12608 1223 79730548
Atrial fibrillation 25.52 13.20 79 12538 197807 79533964
Haemoglobinuria 25.39 13.20 8 12609 783 79730988
Drug intolerance 24.19 13.20 6 12611 264113 79467658
Functional residual capacity increased 23.75 13.20 5 12612 96 79731675
Autoimmune thyroiditis 23.30 13.20 12 12605 4221 79727550
Drug interaction 23.23 13.20 128 12489 415055 79316716
Urinary bladder rupture 22.97 13.20 5 12612 113 79731658
Cardiogenic shock 21.93 13.20 30 12587 41884 79689887
Blood cyanide increased 21.08 13.20 4 12613 44 79731727
Pulmonary alveolar haemorrhage 20.67 13.20 16 12601 11441 79720330
Completed suicide 19.92 13.20 7 12610 245760 79486011
Thyroiditis 19.59 13.20 11 12606 4594 79727177
Hepatitis 19.39 13.20 33 12584 55694 79676077
Respiratory syncytial virus infection 18.88 13.20 14 12603 9388 79722383
Respiratory tract haemorrhage 18.87 13.20 8 12609 1815 79729956
Cholestatic liver injury 18.87 13.20 11 12606 4930 79726841
Electrocardiogram QT prolonged 18.67 13.20 43 12574 90343 79641428
Arthropathy 18.34 13.20 3 12614 177108 79554663
Mucocutaneous candidiasis 18.19 13.20 4 12613 95 79731676
Tonsillitis 18.16 13.20 12 12605 6702 79725069
Urine leukocyte esterase positive 18.03 13.20 10 12607 4081 79727690
Thyroid haemorrhage 17.84 13.20 4 12613 104 79731667
Sopor 17.84 13.20 24 12593 32986 79698785
Acquired epidermolysis bullosa 17.66 13.20 4 12613 109 79731662
Glycosuria 17.47 13.20 8 12609 2180 79729591
Coagulation time shortened 16.77 13.20 5 12612 407 79731364
Insulin autoimmune syndrome 16.53 13.20 5 12612 427 79731344
Jaundice 16.50 13.20 30 12587 53319 79678452
Thyroidectomy 16.32 13.20 6 12611 936 79730835
Oropharyngeal pain 16.32 13.20 46 12571 109307 79622464
Thyroid dermatopathy 16.16 13.20 3 12614 29 79731742
Neuroglycopenia 15.97 13.20 5 12612 479 79731292
Tonsillitis bacterial 15.94 13.20 4 12613 170 79731601
Product use in unapproved indication 15.91 13.20 80 12537 250279 79481492
Ventricular septal defect 15.61 13.20 5 12612 516 79731255
Antineutrophil cytoplasmic antibody 15.57 13.20 3 12614 36 79731735
Hypersensitivity vasculitis 15.45 13.20 11 12606 6932 79724839
Infusion related reaction 14.88 13.20 9 12608 230228 79501543
Toxic nodular goitre 14.71 13.20 3 12614 49 79731722
Metabolic function test abnormal 14.65 13.20 4 12613 237 79731534
Synovitis 14.65 13.20 3 12614 150731 79581040
Exposure during pregnancy 14.56 13.20 42 12575 101090 79630681
Pericardial haemorrhage 14.56 13.20 9 12608 4486 79727285
Cholestasis 14.49 13.20 28 12589 52081 79679690
Therapeutic product effect decreased 14.47 13.20 4 12613 163859 79567912
Mouth swelling 14.42 13.20 10 12607 6041 79725730
Tri-iodothyronine increased 14.40 13.20 4 12613 253 79731518
Tri-iodothyronine free increased 14.26 13.20 4 12613 262 79731509
Premature delivery 14.14 13.20 18 12599 23449 79708322
Symptom masked 14.06 13.20 6 12611 1384 79730387
Pure white cell aplasia 13.82 13.20 3 12614 67 79731704
Urine ketone body present 13.78 13.20 8 12609 3557 79728214
Immune-mediated hepatitis 13.60 13.20 8 12609 3648 79728123
Hypoglycaemia 13.49 13.20 41 12576 101553 79630218
Pleural effusion 13.47 13.20 52 12565 145210 79586561
Eosinophilic pleural effusion 13.30 13.20 4 12613 335 79731436

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H03BB02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
ANTITHYROID PREPARATIONS
Sulfur-containing imidazole derivatives
ATC H03BB52 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
ANTITHYROID PREPARATIONS
Sulfur-containing imidazole derivatives
MeSH PA D013956 Antithyroid Agents
MeSH PA D006727 Hormone Antagonists
FDA MoA N0000175917 Thyroid Hormone Synthesis Inhibitors
FDA EPC N0000175918 Thyroid Hormone Synthesis Inhibitor
CHEBI has role CHEBI:50671 antithyroid drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperthyroidism indication 34486009 DOID:7998
Thyrotoxic crisis off-label use 29028009 DOID:12837
Agranulocytosis contraindication 17182001 DOID:12987
Hypothyroidism contraindication 40930008 DOID:1459
Factor II deficiency contraindication 73975000
Leukopenia contraindication 84828003 DOID:615
Pancytopenia contraindication 127034005 DOID:12450
Liver function tests abnormal contraindication 166603001
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

ProductApplicantIngredients
Felimazole Dechra, Ltd. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thyroid peroxidase Enzyme INHIBITOR IC50 5.57 WOMBAT-PK CHEMBL
Lactoperoxidase Enzyme IC50 4.93 CHEMBL
Taste receptor type 2 member 38 GPCR AGONIST EC50 4.01 IUPHAR
Lactoperoxidase Enzyme IC50 5.08 CHEMBL
Dopamine beta-hydroxylase Enzyme Ki 4.35 CHEMBL

External reference:

IDSource
4017434 VUID
N0000145822 NUI
D00401 KEGG_DRUG
4017434 VANDF
C0025644 UMLSCUI
CHEBI:50673 CHEBI
MMZ PDB_CHEM_ID
CHEMBL1515 ChEMBL_ID
DB00763 DRUGBANK_ID
6649 IUPHAR_LIGAND_ID
1349907 PUBCHEM_CID
224936 RXNORM
2293 MMSL
31962 MMSL
5073 MMSL
d00290 MMSL
002139 NDDF
37656002 SNOMEDCT_US
404864000 SNOMEDCT_US
D008713 MESH_DESCRIPTOR_UI
4198 INN_ID
554Z48XN5E UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 0185-0205 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 0185-0210 TABLET 10 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 23155-070 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 23155-070 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 23155-071 TABLET 10 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 23155-071 TABLET 10 mg ORAL ANDA 19 sections
Methimazole Human Prescription Drug Label 1 33342-335 TABLET 5 mg ORAL ANDA 19 sections
Methimazole Human Prescription Drug Label 1 33342-336 TABLET 10 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 42254-008 TABLET 5 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 42254-009 TABLET 10 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 49884-640 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 49884-640 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 49884-641 TABLET 10 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 49884-641 TABLET 10 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-2366 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-3334 TABLET 5 mg ORAL ANDA 20 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-6536 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 51293-820 TABLET 5 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 51293-821 TABLET 10 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 53808-0850 TABLET 10 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 53808-0949 TABLET 10 mg ORAL ANDA 18 sections
METHIMAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 53808-1044 TABLET 10 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 54868-5135 TABLET 10 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 54868-6071 TABLET 5 mg ORAL ANDA 18 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 60429-380 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 60429-380 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 60429-381 TABLET 10 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 60429-381 TABLET 10 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 60687-357 TABLET 5 mg ORAL ANDA 19 sections
Methimazole HUMAN PRESCRIPTION DRUG LABEL 1 60687-357 TABLET 5 mg ORAL ANDA 19 sections